“B-Logic” Debuts at Kingpins Amsterdam
Five Companies Unite to Reimagine Denim and Showcase Sustainable Solutions
In a bold move toward redefining denim, five trailblazing companies — Circulose, iTextiles®, Labor Made Inc., Neela, and The LYCRA Company — are joining forces to launch B-Logic: The Logical Future of Denim at Kingpins Amsterdam, October 15 – 16. Sugar Factory visitors can explore the sustainable collection of denim and wovens on the mezzanine level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013240355/en/

In a bold move toward redefining denim, five trailblazing companies — Circulose, iTextiles®, Labor Made Inc., Neela, and The LYCRA Company — are joining forces to launch B-Logic: The Logical Future of Denim at Kingpins Amsterdam, October 15 – 16, 2025.
Short for Being Logical, B-Logic is a visionary collaboration that takes a thoughtful and rational approach to developing the next generation of modern, sustainable denim. Every decision, from fiber selection to final construction, was made with purpose, harmony, and responsibility, offering the industry a more sustainable path forward.
Showcasing Sustainable Style
The B-Logic collection features nine curated looks — spanning tops, bottoms, denim, and wovens — for both men and women. Inspired by iconic denim and workwear looks from the 1920s to the 1940s, these garments offer a more modern and minimalist take on classic denim, balancing aesthetics with environmental integrity.
Inside the Fabric
The B-Logic collection integrates the following breakthrough materials and technologies:
- LYCRA® brand fibers deliver comfort stretch to B-Logic. Commercially available later this year, and made from 70 percent plant-based inputs, renewable LYCRA® EcoMade fiber is a drop-in solution that provides equivalent performance to traditional fiber. Also featured: LYCRA® ADAPTIV fiber, LYCRA® T400® fiber, and LYCRA® DUAL COMFORT fabric technology.
- CIRCULOSE® Viscose and CIRCULOSE® Lyocell bring circular innovation to the collection. Both are made using CIRCULOSE®, a pioneering material crafted entirely from 100% discarded cotton textiles. Through advanced technology, cotton waste is transformed into soft, high-quality pulp and fibers, offering the same luxurious feel as virgin materials while closing the loop on textile waste. Fibers made with CIRCULOSE® work in harmony with the foundational fibers for this collection; regenagri and U.S. Cotton.
Denim Reimagined
B-Logic goes beyond a product launch — it ushers in a new era of denim innovation and advances circularity. By merging advanced science and sustainability with design and storytelling, the five collaborators present a vision of fashion as a cycle of renewal, beauty, and purpose, challenging the notion of apparel as disposable and reframing it as enduring, valuable, and conscious.
The collection represents the blueprint for tomorrow’s denim — a thoughtful, responsible approach shaped by the collaboration of its creators:
- Circulose: A Swedish sustain-tech company with a patented process that enables the recycling of cellulosic textile waste, transforming it into a new material called CIRCULOSE®.
- iTextiles®: The strategic enabler aligning partners, technologies, and market opportunities to ensure B-Logic drives meaningful impact across the industry.
- Labor Made Inc.: A design consultancy that bridges innovation with creativity and craftsmanship, its founder, Gordon Muir, designed the B-Logic collection.
- Neela: A Pakistan-based fabric maker that brings these innovations to life by weaving them into fabrics and garments that balance style, function, and responsibility.
- The LYCRA Company: A global leader in developing sustainable and innovative fiber and technology solutions for the apparel industry.
“We’re thrilled to collaborate with Circulose, iTextiles®, Labor Made Inc., and Neela to prove that sustainability isn’t a compromise — it’s a catalyst for innovation,” said Ebru Ozaydin, global product category director – denim, wovens and RTW, at The LYCRA Company. “By integrating renewable fibers into responsible fabrics through thoughtful design and market alignment, we’ve proven that sustainability delivers both beauty and business value. B-Logic demonstrates that denim — and fashion — can be renewable, scalable, and purposeful.”
The collaborators will discuss B-Logic on October 15 at 2:00 p.m. in the Jeanius Hub, or visit the stands of any of the exhibiting companies at Kingpins Amsterdam.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at thelycracompany.com.
LYCRA® is a trademark of The LYCRA Company.
About Circulose
Circulose is a Swedish sustain-tech company that developed a patented process, which enables the recycling of cellulosic textile waste, transforming it into a new material called CIRCULOSE®. Fast Company named Circulose (formerly Renewcell) one of the World’s Most Innovative Companies in 2021 and was a winner of the 2023 World Changing Ideas Awards. CIRCULOSE® was also included on TIME Magazine’s list of the 100 Best Inventions 2020. Founded by innovators from Stockholm’s KTH Royal Institute of Technology in 2012, the award-winning company’s vision is to make fashion circular. To learn more, please visit www.circulose.com.
CIRCULOSE® is a trademark of Circulose.
About Neela
Neela by Sapphire Fibres Ltd. is a denim mill by Sapphire group based in Pakistan, specializing in sustainable, innovative fabric solutions for global fashion brands. Established in 2016, with state-of-the-art technologies and ethical design approach, its diversified fabric range focuses on advanced constructions, eco-friendly fibers, and fashion forward design aesthetics for customers across the US and Europe.
About Labor Made Inc.
Labor Made Inc. is a strategic design, innovation, and marketing consultancy based in Hiroshima, Japan. With over 30 years of expertise and market insight, it combines creative design, innovation, branding, and culture to craft tailored, human-centred solutions and collections from fibre to floor that drive meaningful impact for its clients.
About iTextiles®
iTextiles® is a leading textile solutions company founded in 2006, managing the entire value chain from fibers to fabrics and chemicals. Partnering with global suppliers, manufacturers, and retailers, we deliver sustainable, innovative, and high-performance solutions across fashion, workwear, military, and home textiles. Our focus on innovation and quality helps accelerate value creation for our partners and the wider textile industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013240355/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom